Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "/fulltext " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.thelancet.com/journals/lanonc/article/PII" to "https://doi.org/10.1016/") |
||
| Line 16: | Line 16: | ||
==EANO== | ==EANO== | ||
| − | *'''2016:''' [https:// | + | *'''2016:''' [https://doi.org/10.1016/S1470-2045(16)30321-7 EANO guidelines for the diagnosis and treatment of meningiomas] [https://pubmed.ncbi.nlm.nih.gov/27599143 PubMed] |
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
Revision as of 20:33, 16 September 2022
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
Unresectable, all lines of therapy
Placebo
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Ji et al. 2015 (SWOG S9005) | 1992-1998 | Phase 3 (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701